Literature DB >> 35371469

Ethical challenges in managing unvaccinated patients receiving chronic in-centre haemodialysis.

Gaetano Alfano1, Francesco Fontana1, Niccolò Morisi2, Giacomo Mori1, Gianni Cappelli1, Riccardo Magistroni1, Gabriele Donati1.   

Abstract

Insufficient vaccine coverage and dominance of the more transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are the leading causes of the continued spread of coronavirus disease 2019 (COVID-19) worldwide. To curb the surge in infections, COVID-19 vaccination has been advocated as a priority measure, especially for frail populations and people at high risk of exposure. Patients on in-centre maintenance haemodialysis (HD) embody both conditions. They are at high risk of severe COVID-19 consequences due to their advanced age and weakened immune system and carry an increased risk of SARS-CoV-2 transmission within shared dialysis rooms and public vehicles. Vaccination of the entire HD population is therefore the most effective strategy to protect patients from the dire consequences of COVID-19. Unfortunately, a minority of patients still express COVID-19 vaccine hesitancy. The management of this group of patients, who have the full right to HD treatment, poses demanding problems from a patient safety perspective. The placement of unvaccinated patients within the dialysis room and the protection of all vaccinated patients are some of the most urgent problems the nephrologist faces during the COVID-19 pandemic. In light of these COVID-19-driven changes, an ethical reflection on the management of unvaccinated patients appears crucial to act responsibly and contribute to the health promotion of dialysis patients.
© The Author(s) 2021. Published by Oxford University Press on behalf of the ERA.

Entities:  

Keywords:  COVID-19; dialysis; ethics; haemodialysis; screening; vaccine

Year:  2021        PMID: 35371469      PMCID: PMC8967673          DOI: 10.1093/ckj/sfab276

Source DB:  PubMed          Journal:  Clin Kidney J        ISSN: 2048-8505


‘Why do I need another nasal swab if I am asymptomatic?’ claimed a patient on maintenance dialysis before starting the dialysis session. ‘The reasons are simple enough to comprehend. You returned from a holiday dialysis centre without a recent negative COVID-19 test’, replied the doctor. ‘Furthermore, if I am not mistaken, you are also unvaccinated’, the doctor said, speaking to the patient from the other side of the dialysis bed. This scenario represents one of the many cross-sections of daily life in a haemodialysis (HD) unit during the time of coronavirus disease 2019 (COVID-19). Testing for COVID-19 and anti-COVID vaccination have become the main interventions for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Negative COVID-19 testing, regardless of adherence to vaccination, is a critical prerequisite when uninfected HD patients move between dialysis units. Generally, each dialysis centre demands proof of negative testing within 48–72 h before their arrival, which means tests are required on the way to and the way back from another unit. Similar regulations are applied for domestic and international travel, according to the country’s requirements. For instance, people are allowed to board an aircraft or ship if they show proof of a recent negative COVID-19 test. For residents undergoing vaccination, a ‘vaccine passport’ certificate has been issued. This ‘green pass’ allows the possessors, in the absence of symptoms, to access otherwise restricted indoor places such as restaurants, museums, gyms and hotels. The first countries that embraced this policy were Israel and Italy. In Italy, the green pass is now mandatory for all private and public sector employees to continue working unless they provide proof of negative COVID-19 test results performed within 48 (antigenic test) or 72 h (molecular test). The proposal for the green pass evolved from the generalized desire to return to normality after a long period of social restriction while attempting to limit the spread of COVID-19 by incentivizing vaccination uptake. However, although the green pass has encouraged some hesitant individuals, not everyone is willing to be vaccinated [1]. For this group of people, entry to certain locations and benefits of a gradual easing of COVID-19 restrictions continue to be forbidden. Likewise, many activities of unvaccinated patients on chronic HD may be further limited by the lack of a green pass. An exception is the delivery of lifesaving treatments such as in-centre HD. Given these circumstances, the question that arises is ‘How should dialysis units approach unvaccinated in-centre HD patients given that they have a right to and require regular treatment?’ Dialysis units are small communities that have been exposed to undue risk from COVID-19. Per-population cases and deaths among dialysis patients have exceeded the general population by 100-fold in some countries [2]. It is universally acknowledged that in-centre HD patients have an increased risk of SARS-CoV-2 transmission because they share dialysis, waiting and dressing rooms as well as dialysis transportation services with other patients [3]. Furthermore, these patients show increased susceptibility to severe COVID-19 due to their advanced age and weakened immune system [4]. These conditions also impact the efficacy of the vast vaccination campaign launched in high- and upper-middle-income countries, since dialysis patients might remain wholly or partially unprotected by a standard cycle of COVID-19 vaccination. Hence, whereas some HD patients are willing to mitigate the risk of SARS-CoV-2 infection with a third booster dose [5], a minority of patients (∼3% in our centre) still express uncertainty about vaccination. This proportion, although numerically small, poses significant logistic and ethical difficulties in the management of these patients (Figure 1). On the one hand, unvaccinated patients have the full right to access healthcare, including HD. On the other hand, other patients and healthcare workers also have a right to be protected from an unvaccinated person who may pose a health risk to them. In the absence of a satisfactory solution, here we discuss various ethical considerations arising around the challenging placement of these patients within the dialysis unit, an issue that requires urgent deliberation (Table 1).
FIGURE 1:

Practical issues related to the unvaccinated patients on in-centre maintenance haemodialysis.

Table 1.

Ethical concerns in the management of in-centre HD patients with COVID-19 vaccine hesitancy

IssuesEthical concerns
Placement of unvaccinated patients within the dialysis unitDiscrimination
 Isolation of unvaccinated patientsHigh risk of COVID-19 outbreak
Breaches of privacy and confidentiality
 Mix of unvaccinated and vaccinated patients within the same roomUnprotection of vaccinated patients
Miscellaneous
 TransportationUnprotection of the driver and vaccinated patients
 Access to the dialysis unitUnprotection of healthcare workers
 Access to health services other than dialysisUnprotection of vaccinated patients and healthcare workers
 Waiting list for kidney transplantationPoor medication adherence
Practical issues related to the unvaccinated patients on in-centre maintenance haemodialysis. Ethical concerns in the management of in-centre HD patients with COVID-19 vaccine hesitancy One potential solution may appear to be gathering all patients who refuse vaccination in a separate room as is current practice for hepatitis B virus–positive patients. In this way, vaccinated patients would be somewhat shielded from the risk of contagion from unvaccinated patients. Although this solution appears logistically fair, it does not act in the best interest of the patient and contrasts with the principle of prioritizing patient's safety for the following reasons: Patients who are reluctant to be vaccinated are extremely vulnerable to COVID-19. Gathering all unvaccinated patients in one room may increase the risk of SARS-CoV-2 transmission among the most vulnerable and may have disastrous consequences in case of a COVID-19 outbreak. The lack of immunization against COVID-19 does not mean SARS-CoV-2 infection and therefore cannot be compared to a communicable infectious disease such as hepatitis B. This implies that confining measures are unnecessary for unvaccinated individuals without COVID-19. Isolation may be perceived as unfair discrimination against people who deny vaccination. Confining unvaccinated patients could also jeopardize the confidentiality of the vaccination status, which instead should be guaranteed as much as possible, especially for unvaccinated people with personal or religious objections. A fairer solution may therefore be to mix unvaccinated with vaccinated HD patients while all shield appropriately with masks, handwashing and distancing. In order to achieve a somewhat local herd immunity threshold, physicians may take into account the immunological response of the other patients in the room. In addition, to offer the best standard of care and reduce the risk of COVID-19 spread, unvaccinated patients would be required to undergo frequent testing. In parallel with the green pass regulation, COVID-19 testing may be performed, in a high-resource setting, every 48–72 h, which will coincide approximately with each dialysis session. In conclusion, the management of unvaccinated patients in dialysis units imposes a series of ethical challenges that are not easy to resolve. No clear indications exist on the best way to protect vaccinated HD patients from unvaccinated ones and vice versa in terms of timing and modality (antigenic or molecular test) of anti-COVID-19 screening. Patient education should be encouraged because it has been shown to be an effective tool in increasing vaccine acceptance. However, in the meantime, as educational interventions yield positive results and herd immunity nears, frequent testing of unvaccinated patients may be a temporal solution to reduce the risk of COVID-19 transmission within dialysis units.
  5 in total

1.  Incentivizing Vaccination Uptake: The "Green Pass" Proposal in Israel.

Authors:  Rachel Wilf-Miron; Vicki Myers; Mor Saban
Journal:  JAMA       Date:  2021-04-20       Impact factor: 56.272

Review 2.  The frail world of haemodialysis patients in the COVID-19 pandemic era: a systematic scoping review.

Authors:  Gaetano Alfano; Annachiara Ferrari; Riccardo Magistroni; Francesco Fontana; Gianni Cappelli; Carlo Basile
Journal:  J Nephrol       Date:  2021-08-21       Impact factor: 3.902

3.  Worldwide Early Impact of COVID-19 on Dialysis Patients and Staff and Lessons Learned: A DOPPS Roundtable Discussion.

Authors:  Bruce M Robinson; Murilo Guedes; Mohammed Alghonaim; Aleix Cases; Indranil Dasgupta; Liangying Gan; Stefan H Jacobson; Talerngsak Kanjanabuch; Yong-Lim Kim; Werner Kleophas; Laura Labriola; Rachel L Perlman; Gianpaolo Reboldi; Vesh Srivatana; Rita S Suri; Kazuhiko Tsuruya; Pablo Urena Torres; Ronald L Pisoni; Roberto Pecoits-Filho
Journal:  Kidney Med       Date:  2021-05-14

4.  At least 156 reasons to prioritize COVID-19 vaccination in patients receiving in-centre haemodialysis.

Authors:  Christian Combe; Alexander H Kirsch; Gaetano Alfano; Valerie A Luyckx; Rukshana Shroff; Mehmet Kanbay; Frank van der Sande; Carlo Basile
Journal:  Nephrol Dial Transplant       Date:  2021-03-29       Impact factor: 5.992

5.  Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis.

Authors:  Marine Dekervel; Nicolas Henry; Massimo Torreggiani; Lise-Marie Pouteau; Jean-Paul Imiela; Chloé Mellaza; Anne-Sophie Garnier; Amaury Dujardin; Marine Asfar; Alexandra Ducancelle; Axelle Paquin; Sophie Blanchi; Virginie Besson; Giorgina Barbara Piccoli; Jean-François Augusto
Journal:  Clin Kidney J       Date:  2021-08-13
  5 in total
  3 in total

Review 1.  Impact of the COVID-19 pandemic on the kidney community: lessons learned and future directions.

Authors:  Duvuru Geetha; Andreas Kronbichler; Megan Rutter; Divya Bajpai; Steven Menez; Annemarie Weissenbacher; Shuchi Anand; Eugene Lin; Nicholas Carlson; Stephen Sozio; Kevin Fowler; Ray Bignall; Kathryn Ducharlet; Elliot K Tannor; Eranga Wijewickrama; Muhammad I A Hafidz; Vladimir Tesar; Robert Hoover; Deidra Crews; Charles Varnell; Lara Danziger-Isakov; Vivekanand Jha; Sumit Mohan; Chirag Parikh; Valerie Luyckx
Journal:  Nat Rev Nephrol       Date:  2022-08-24       Impact factor: 42.439

2.  Efficacy of SARS-CoV-2 Vaccination in Dialysis Patients: Epidemiological Analysis and Evaluation of the Clinical Progress.

Authors:  Giovanni Mosconi; Michela Fantini; Matteo Righini; Marta Flachi; Simona Semprini; Lilio Hu; Francesca Chiappo; Barbara Veterani; Katia Ambri; Franca Ferrini; Catia Milanesi; Antonio Giudicissi; Gaetano La Manna; Angelo Rigotti; Andrea Buscaroli; Vittorio Sambri; Maria Cappuccilli
Journal:  J Clin Med       Date:  2022-08-12       Impact factor: 4.964

3.  COVID-19 Rapid Antigen Test Screening in Patients on Hemodialysis.

Authors:  Gaetano Alfano; Roberta Scarmignan; Niccolò Morisi; Francesco Fontana; Silvia Giovanella; Giulia Ligabue; Laura Rofrano; William Gennari; Monica Pecorari; Mariacristina Gregorini; Gianni Cappelli; Riccardo Magistroni; Gabriele Donati
Journal:  Int J Nephrol       Date:  2022-09-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.